These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 34102935)

  • 1. Potential experimental immune checkpoint inhibitors for the treatment of cancer of the liver.
    Hewitt DB; Rahnemai-Azar AA; Pawlik TM
    Expert Opin Investig Drugs; 2021 Aug; 30(8):827-835. PubMed ID: 34102935
    [No Abstract]   [Full Text] [Related]  

  • 2. Emerging immune checkpoint inhibitors for the treatment of hepatocellular carcinoma.
    Chan LL; Chan SL
    Expert Opin Emerg Drugs; 2021 Mar; 26(1):39-52. PubMed ID: 33724135
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical outcomes of immune checkpoint inhibitors in unresectable or metastatic combined hepatocellular-cholangiocarcinoma.
    Jang YJ; Kim EJ; Kim HD; Kim KP; Ryu MH; Park SR; Choi WM; Lee D; Choi J; Shim JH; Kim KM; Lim YS; Lee HC; Ryoo BY; Yoo C
    J Cancer Res Clin Oncol; 2023 Aug; 149(10):7547-7555. PubMed ID: 36971796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Milestones in the pathogenesis and management of primary liver cancer.
    Nault JC; Cheng AL; Sangro B; Llovet JM
    J Hepatol; 2020 Feb; 72(2):209-214. PubMed ID: 31954486
    [No Abstract]   [Full Text] [Related]  

  • 5. Biochemical predictors of response to immune checkpoint inhibitors in unresectable hepatocellular carcinoma.
    Rizzo A; Brandi G
    Cancer Treat Res Commun; 2021; 27():100328. PubMed ID: 33549983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer Immunotherapy - Immune Checkpoint Inhibitors in Hepatocellular Carcinoma.
    Bai J; Liang P; Li Q; Feng R; Liu J
    Recent Pat Anticancer Drug Discov; 2021; 16(2):239-248. PubMed ID: 33583384
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beyond First-Line Immune Checkpoint Inhibitor Therapy in Patients With Hepatocellular Carcinoma.
    Sharma R; Motedayen Aval L
    Front Immunol; 2021; 12():652007. PubMed ID: 33790915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overcoming Resistance to Immune Checkpoint Blockade in Liver Cancer with Combination Therapy: Stronger Together?
    Werner W; Kuzminskaya M; Lurje I; Tacke F; Hammerich L
    Semin Liver Dis; 2024 May; 44(2):159-179. PubMed ID: 38806159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanistic Rationales Guiding Combination Hepatocellular Carcinoma Therapies Involving Immune Checkpoint Inhibitors.
    Cheu JW; Wong CC
    Hepatology; 2021 Oct; 74(4):2264-2276. PubMed ID: 33811765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic Therapy for Primary Liver Tumors: Cholangiocarcinoma and Hepatocellular Carcinoma.
    Sadeghi S; Bejjani A; Finn RS
    Surg Oncol Clin N Am; 2019 Oct; 28(4):695-715. PubMed ID: 31472914
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The safety and efficacy of lenvatinib combined with immune checkpoint inhibitors therapy for advanced hepatocellular carcinoma.
    Wang Y; Jiang M; Zhu J; Qu J; Qin K; Zhao D; Wang L; Dong L; Zhang X
    Biomed Pharmacother; 2020 Dec; 132():110797. PubMed ID: 33068935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic therapy for hepatocellular carcinoma and cholangiocarcinoma.
    Chung V
    Surg Oncol Clin N Am; 2015 Jan; 24(1):187-98. PubMed ID: 25444475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting YAP1 to improve the efficacy of immune checkpoint inhibitors in liver cancer: mechanism and strategy.
    Gao Y; Gong Y; Lu J; Hao H; Shi X
    Front Immunol; 2024; 15():1377722. PubMed ID: 38550587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiation and Immune Checkpoint Inhibitors: Combination Therapy for Treatment of Hepatocellular Carcinoma.
    Chami P; Diab Y; Khalil DN; Azhari H; Jarnagin WR; Abou-Alfa GK; Harding JJ; Hajj J; Ma J; El Homsi M; Reyngold M; Crane C; Hajj C
    Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38069095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Evolving Landscape of Checkpoint Inhibitor Combination Therapy in the Treatment of Advanced Hepatocellular Carcinoma.
    Liu L; Qin S; Zhang Y
    Target Oncol; 2021 Mar; 16(2):153-163. PubMed ID: 33528759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune Checkpoint Inhibitors as Monotherapy or Within a Combinatorial Strategy in Advanced Hepatocellular Carcinoma.
    Guardascione M; Toffoli G
    Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32878115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of dual checkpoint inhibitors in a patient with a mixed hepatocellular cholangiocarcinoma.
    Sucre S; Bullock A; Peters ML
    BMJ Case Rep; 2024 May; 17(5):. PubMed ID: 38697678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Developing targeted therapeutics for hepatocellular carcinoma: a critical assessment of promising phase II agents.
    Amadeo E; Foti S; Camera S; Rossari F; Persano M; Lo Prinzi F; Vitiello F; Casadei-Gardini A; Rimini M
    Expert Opin Investig Drugs; 2024 Aug; 33(8):839-849. PubMed ID: 39039690
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatocellular carcinoma: an update on investigational drugs in phase I and II clinical trials.
    Noonan A; Pawlik TM
    Expert Opin Investig Drugs; 2019 Nov; 28(11):941-949. PubMed ID: 31590579
    [No Abstract]   [Full Text] [Related]  

  • 20. Strategies to enhance the response of liver cancer to pharmacological treatments.
    Marin JJG; Macias RIR; Asensio M; Romero MR; Temprano AG; Pereira OR; Jimenez S; Mauriz JL; Di Giacomo S; Avila MA; Efferth T; Briz O
    Am J Physiol Cell Physiol; 2024 Jul; 327(1):C11-C33. PubMed ID: 38708523
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.